ADAMS RESPIRATORY THERAPEUTICS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2007

Adams Respiratory Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware	000-51445	75-2725552

(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4 Mill Ridge Lane, Chester, New Jersey 07930

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 879-1400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On February 7, 2007, Adams Respiratory Therapeutics, Inc. (the “Company”) issued a press release announcing its results of operations for the second fiscal quarter ended December 31, 2006. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

On February 7, 2007, the Company will conduct a conference call to review its sales and earnings results for the second fiscal quarter ended December 31, 2006. A live audio webcast of the conference call will include a slide presentation that contains, among other things, forward-looking information about Adams Respiratory Therapeutics, Inc. and its business. The slides that the Company will use in this presentation are furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

Certain statements in the slide presentation constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management’s expectations and are based on currently available information. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the continued success of the Company’s existing products and the successful commercialization of future products; the Company’s ability to complete the clinical trials of Erdosteine and successfully commercialize it in the United States; leverage of the Mucinex brand name to increase market share; continued and increased competition; the Company’s ability to in-license or acquire new products and brands and successfully develop new products; the FDA’s removal from the market of products similar to Mucinex D, Mucinex DM and future products; the Company’s ability to maintain increased production capacity; the Company’s ability to preserve and successfully defend its patent position; the FDA’s denial of the Company’s NDA for a prescription cough suppressant; the Company’s ability to compete against other branded products, as well as against generic competition; the severity of the cough and cold season and other risk factors set forth under Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006, and under Item 1A. Risk Factors in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2006.

The information furnished pursuant to Item 2.02 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On February 1, 2007, David P. Becker, Chief Financial and Administrative Officer and Treasurer of the Company, notified the Company that he was resigning to accept a position as chief executive officer of a privately held medical diagnostics company. Mr. Becker’s resignation from his position as Chief Financial and Administrative Officer and Treasurer is effective February 7, 2007, but he will remain as an employee of the Company until February 28, 2007.

(c) On February 7, 2007, the Company announced the promotion of Rita M. O’Connor to Chief Financial Officer and Treasurer to succeed Mr. Becker.

Ms. O’Connor, 38, has been the Company’s Senior Vice President and Corporate Controller since July 1, 2006. Ms. O’Connor served as the Company’s Vice President and Corporate Controller from August 2005 to July 2006, and prior to that time, as the Company’s Executive Director Accounting and Finance (Controller). Before she joined the Company in November 2004, Ms. O’Connor spent seven years at

Schering-Plough Corporation in a series of positions of increasing responsibility within the corporate global finance department. More recently, she was senior director planning & reporting within Schering-Plough Corporation’s corporate controller’s group. Ms. O’Connor began her career in the audit department at Deloitte and Touche, where she progressed to audit manager, including a two-year program in Deloitte’s National Office technical accounting research department. Ms. O’Connor has a B.S. degree in accounting from Rutgers University and is a certified public accountant.

There are no arrangements between Ms. O’Connor and any other person pursuant to which Ms. O’Connor was selected as an officer, nor are there any transactions to which the Company was or is a participant and in which Ms. O’Connor has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

In connection with Ms. O’Connor’s promotion, Ms. O’Connor will receive an annual base salary of $290,000 and will be eligible for the performance-based bonus authorized by the Company’s Board of Directors for certain senior executive officers and key employees. Ms. O’Connor will also be eligible to receive awards granted pursuant to the Company’s 2005 Stock Incentive Plan. In addition, the Company will enter into an income security agreement with Ms. O’Connor. Under the terms of the income security agreement, if the Company terminates Ms. O’Connor without cause or if Ms. O’Connor resigns for good reason (as defined in the agreement) within one year after a change in control, she will receive severance benefits in an amount equal to her earned but unpaid salary, any awarded but unpaid bonus from the previous fiscal year and one year of annual base salary. In addition, Ms. O’Connor and her dependents will continue to receive health benefits for one year following the date of termination. The income security agreement also provides that Ms. O’Connor agrees not to disclose confidential information or for one year after termination, compete with the Company or recruit the Company’s employees.

Item 8.01. Other Events

On February 7, 2007, the Company issued a press release announcing the resignation of David P. Becker as Chief Financial and Administrative Officer and Treasurer of the Company. On February 7, 2007, the Company issued a press release announcing the appointment of Rita M. O’Connor as Chief Financial Officer and Treasurer of the Company. A copy of the press releases are attached hereto as Exhibits 99.3 and 99.4, respectively, and are incorporated herein by reference in their entirety.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:


Exhibit
Number		Description
99.1		Press release dated February 7, 2007, announcing results of operations.

99.2		Slide presentation to be presented February 7, 2007.

99.3		Press release dated February 7, 2007, announcing resignation of David P. Becker.

99.4		Press release dated February 7, 2007, announcing appointment of Rita M. O’Connor.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ADAMS RESPIRATORY THERAPEUTICS, INC. (Registrant)

February 7, 2007	By:	/s/ Walter E. Riehemann

		Walter E. Riehemann
		Executive Vice President, General Counsel, Chief
		Compliance Officer and Secretary

EXHIBIT INDEX


Exhibit
Number		Description
99.1		Press release dated February 7, 2007, announcing results of operations.

99.2		Slide presentation to be presented February 7, 2007.

99.3		Press release dated February 7, 2007, announcing resignation of David P. Becker.

99.4		Press release dated February 7, 2007, announcing appointment of Rita M. O’Connor.

Exhibit 99.1

ADAMS RESPIRATORY THERAPEUTICS REPORTS
FISCAL 2007 SECOND QUARTER FINANCIAL RESULTS
Strong top-line performance driven by higher sales of
Mucinex^® DM, Delsym^®, and Children’s Mucinex^®

Second Quarter Financial Highlights:

	•		Net sales increased 75% to $110.6 million.

	•		Selling, marketing and administrative expenses increased $26 million to $56 million, including investments in selling and consumer marketing programs.

	•		Diluted earnings per share increased 17% to $0.34, inclusive of a non-cash, pre-tax charge of $2.7 million, or $0.04 per diluted share, related to the AlleRx^™ royalty interest.

Second Quarter Operational Highlights:

	•		Gained a leading position in the over-the-counter (OTC) cough, cold, allergy, sinus (C/C/A/S) category with a total share of 11.9 percent of the market, according to Information Resources Inc. (IRI) data for the 4-week period ending Dec. 31, 2006, an increase of 5.2 market share points versus the prior-year period.

	•		Completed the clinical portion of the Phase IIb trial of erdosteine in December. The Company awaits top-line results.

	•		Submitted a New Drug Application (NDA) to the FDA for the first extended-release guaifenesin combination prescription product for cough. (Dec.)

CHESTER, N.J. (Feb. 7, 2007) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced financial results for the fiscal second quarter ended Dec. 31, 2006.

Commenting on the Company’s fiscal 2007 second quarter results, Michael J. Valentino, president and CEO said, “I am really excited by our performance this quarter. We produced solid results and we continued to make significant and strategically important investments to further develop our business. We achieved strong top-line growth across our product line which produced healthy increases in both net income and diluted earnings per share in the fiscal 2007 second quarter.”

Valentino added, “These results clearly demonstrate that we can apply our ‘blueprint for success’ to additional products beyond the core Mucinex franchise. Adams now has a leading position in the OTC C/C/A/S category, and with our adult Mucinex franchise, we are now vying for market leadership. Notably, during this quarter of excellent marketing and retail execution, we also achieved two other significant milestones. First, we submitted a NDA in December for the first prescription product in our current portfolio, which will target the cough market. Second, we completed the clinical portion of the Phase IIb trial for erdosteine. We remain on track to provide a summary of top-line results of this study by the end of March 2007.”

Second Quarter Financial Results

Net sales for the quarter rose 75 percent to $110.6 million from $63.2 million in the fiscal 2006 second quarter. This record growth comes primarily from accelerating Mucinex DM sales growth, ramping sales of the newly acquired Delsym line and the launch of the Children’s Mucinex products.

Income before income taxes increased 12 percent to $19.4 million and diluted earnings per share increased 17 percent to $0.34 in the fiscal 2007 second quarter, inclusive of a non-cash, pre-tax charge of $2.7 million, or $0.04 per diluted share, related to the AlleRx royalty interest. Income before income taxes in the fiscal 2007 second quarter also included spending on various selling and consumer marketing programs to support continued market penetration of our products, as well as product development initiatives. In the prior-year period, income before income taxes and diluted earnings per share were $17.4 million and $0.29, respectively.

The Company’s annual effective tax rate was reduced in the fiscal 2007 second quarter to 35.5 percent from 38.7 percent in the fiscal 2006 second quarter. As previously disclosed in the Company’s fiscal 2007 first quarter earnings press release on Nov. 8, 2006, the change was primarily due to a tax deduction provided to U.S. manufacturers that the Company became eligible for as a result of the July 31, 2006, repurchase of the Fort Worth, Texas, manufacturing assets. The year-over-year decline in the rate was also due to a shift in stock compensation expense from non-deductible incentive stock options to deductible non-qualified stock options.

The Company’s gross margin was 75.9 percent for the fiscal 2007 second quarter, compared to 78.0 percent for the same prior-year period. The gross margin decline was primarily due to a year-over-year change in product mix, including higher sales of lower-margin products such as Children’s Mucinex and Delsym, which are manufactured by third parties.

Product Sales

Total net sales of the adult Mucinex products were $79.0 million in the fiscal 2007 second quarter. Mucinex DM posted net sales of $30.6 million in the fiscal 2007 second quarter, a more than two-fold increase over the prior-year period. The strong performance of Mucinex DM was driven by the product’s year-over-year growth in market share, improved depth and quality of distribution as well as a new advertising campaign for the product. On a sequential basis, net sales of Mucinex DM also accelerated, increasing by $6.4 million or 26 percent from the fiscal 2007 first quarter.

Net sales of Mucinex SE were $39.2 million in the fiscal 2007 second quarter, a decline of $1.6 million, or 4 percent, compared to the prior-year period. Even though individual net sales of Mucinex SE slightly declined during the second quarter, Mucinex DM added $17.9 million in sales to the adult Mucinex franchise.

Mucinex D, launched in late October 2005, recorded net sales of $9.1 million in the fiscal 2007 second quarter, a slight decline from sales of $9.7 million in the prior-year period, which benefited from strong initial trade stocking for the product. Mucinex D has continued to experience year-over-year increases in retail consumption and market share gains.

Net sales of Delsym, acquired by Adams in June 2006, were $18.5 million. Delsym is the only FDA-approved over-the-counter 12-hour liquid cough suppressant. On a sequential basis, Delsym sales more than doubled from $8.2 million recorded in the fiscal 2007 first quarter. The brand has responded rapidly to its first-ever television advertising campaign which launched Oct. 23, 2006. Delsym achieved an all-time high market share of 18.9 percent of the cough syrup segment of the C/C/A/S category, according to IRI data for the 4-weeks ended Dec. 31, 2006, an increase of nearly 6 market share points over the prior-year period.

Net sales of Children’s Mucinex products, launched in August 2006, were $12.6 million in the fiscal 2007 second quarter, a sequential gain of 26 percent or $2.6 million, benefiting from its initial consumer advertising campaign which commenced on Oct. 17, 2006. The Children’s Mucinex line consists of two liquid and two Mini-Melt™ versions of immediate-release guaifenesin. According to IRI, Children’s Mucinex achieved an 8.4 percent share of the branded pediatric segment within the C/C/A/S category for the 4-weeks ended Dec. 31, 2006. Children’s Mucinex products already rank No. 4 in the branded pediatric segment of the category, according to IRI data for the same 4-week period.

Other Events:

	•		Harold F. Oberkfell named Chairman of the Board of Directors. (Jan.)

	•		Filed an appeal brief to the Board of Patent Appeals and Interferences at the United States Patent and Trademark Office in connection with the reexamination proceeding of U.S. Patent No. 6,372,252, covering our guaifenesin delivery system. (Jan.)

	•		Michael J. Valentino elected Vice Chairman of the HealthCare Institute of New Jersey. (Dec.)

	•		Dr. Alan W. Dunton elected to the Board of Directors. (Nov.)

	•		Filed lawsuit against URL/Mutual Pharmaceuticals for patent infringement of our single-ingredient extended-release guaifenesin products. (Oct.)

Business Outlook

•

Selling, Marketing and Administrative Expenses

The Company expects total selling, marketing and administrative expenses for the 2007 fiscal year to range from $168 to $172 million. The higher level of expense compared to fiscal year 2006 is primarily due to the following:

•

Higher consumer marketing expenses.

	•		The Company reiterates its guidance to spend approximately $70 million in consumer advertising during fiscal 2007.

	•		This will consist of approximately $50 million to support the core Mucinex brand, including the new Children’s Mucinex line of products, and approximately $20 million to support the newly acquired Delsym brand.

	•		Higher costs related to the 25 new sales representatives hired in July 2006.

	•		Higher distribution and shipping costs on increased sales volume as well as higher storage fees resulting from increased manufacturing capacity.

	•		Incremental expenses related to the Company’s legal and patent defense. The patent litigation case against URL/Mutual currently has a trial date set for June 26, 2007. As the Company continues to vigorously defend its position, it expects to incur significant legal fees for the remainder of the 2007 fiscal year.

	•		Non-cash stock-based compensation expense, primarily recorded within selling, marketing and administrative expenses, is estimated to be approximately $9 million for fiscal year 2007.

	•		Increased headcount to support the growth in the business.

	•		Higher costs associated with being a public company, including audit and tax-related fees and costs related to compliance projects, such as Section 404 of the Sarbanes-Oxley Act.

•

Product Development Expenses

The Company has narrowed the estimated range for spending on product development projects in fiscal year 2007 to between $29 and $32 million, from its previously estimated range of $30 to $35 million, due primarily to lower-than-anticipated outside service costs. As always, product development expenses are subject to the timing of various events. It is important to note that the Company remains on track with its internal timelines for its ongoing development projects.

•

Included in the annual estimate is approximately $10 to $13 million related to the U.S. development program for erdosteine. The clinical portion Phase IIb study of erdosteine was completed in December 2006. The Company awaits top-line results. The Company expects to report preliminary top-line results from the study by the end of March 2007. Assuming these results are positive, Adams would expect to move forward with Phase III development for erdosteine after an “End of Phase II” meeting with the FDA, which could occur early in fiscal 2008.

•

The projected product development expense for fiscal year 2007 also includes spending on other development projects, including line extensions and products utilizing Adams’ extended-release guaifenesin platform technology in combination with other respiratory ingredients. As previously disclosed, the Company expects to nearly double its product portfolio resulting in about 16 to 18 individual items, and at least 30 stock-keeping-units (SKUs) in fiscal 2008.

•

Gross Margin

The Company continues to anticipate the gross margin for its adult extended-release guaifenesin products to approximate 80 percent of net sales in fiscal 2007. The gross margin for the Children’s Mucinex products should range between 70 to 75 percent of net sales, and the Delsym product line should produce a gross margin in the mid-60 percent range of net product sales.

•

Effective Tax Rate

The Company estimates that its annual effective tax rate for fiscal 2007 will approximate 36.0 percent.

•

Capital Expenditures

Capital improvements are expected to approximate between $3 and $5 million in fiscal 2007, primarily relating to the recently acquired manufacturing operations in Fort Worth, Texas.

Fiscal Second Quarter 2007 Conference Call and Webcast

Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) is scheduled to announce its sales and earnings results for the fiscal second quarter of 2007 on Wednesday, Feb. 7, 2007, before the market opens. At 9:00 a.m. (ET) on that day, Adams management will conduct a conference call to review the fiscal second quarter results.

To listen live to the call, dial 1-866-356-4441 or 1-617-597-5396. A replay of the call will be available starting at approximately 11 a.m. on Feb. 7 through 5 p.m. on Feb. 14. To listen to the replay, dial 1-888-286-8010 or 1-617-801-6888 and enter the participant password 54190613.

A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Adams web site, http://www.adamsrt.com. A replay of the webcast will be available starting at approximately 11 a.m. on Feb. 7 through 5 p.m. on March 7.

PLEASE NOTE: A slide presentation to accompany the audio webcast of the conference call will be available by going to the Investor Relations/News and Events section of Adams’ web site, http://www.adamsrt.com.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

Forward-Looking Statements

This press release contains certain “forward-looking” statements, including the Company’s plans to continue to develop and launch new products, to report results on the erdosteine clinical trials and conduct further clinical trials, to defend its patent position, to maintain improved production capacity and increased sales, and to increase marketing efforts and expand advertising and the Company’s belief and anticipation that the FDA will approve the NDA. Such forward-looking statements can be identified by the words “plan,” “anticipate,” “expect,” and similar expressions and are subject to risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, the Company’s ability to: maintain the success of its existing products and successfully introduce and commercialize new products; extend the long-acting guaifenesin platform to new market segments and build the prescription drug market; effectively rely on third-party manufacturers; achieve projected gross margins; retain sales force personnel; increase expenditures on advertising and marketing; successfully conduct clinical trials; preserve its patent position; obtain the FDA’s approval of the NDA and other risk factors set forth Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006 and under Item 1A. Risk Factors in Adams’ Quarterly Report on Form 10-Q for the period ended September 30, 2006. Except to the extent required by applicable securities laws, Adams is not under any obligation to (and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future events, or otherwise. All statements contained in this press release are made only as of the date of this release.

# # #

Investor/Media Contact: Janet M. Barth (908) 879-2428

Source: Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT)

Adams Respiratory Therapeutics, Inc.
Consolidated Statements of Income
(Amounts in thousands, except per share amounts)


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2006			2005			2006			2005
	(unaudited)
Net sales	$	110,576		$	63,247		$	200,718		$	110,264
Cost of goods sold		26,598			13,920			55,956			22,441

Gross margin		83,978			49,327			144,762			87,823


Selling, marketing & administrative		55,963			29,693			85,946			45,562
Product development		6,727			4,096			13,014			7,522
AlleRx charge		2,699			—			2,699			—
Other, net		(823	)		(1,862	)		(1,702	)		(2,788	)

		64,566			31,927			99,957			50,296


Income before income taxes		19,412			17,400			44,805			37,527
Provision for income taxes		6,889			6,734			16,104			14,473

Net income	$	12,523		$	10,666		$	28,701		$	23,054


Income per common share
Basic	$	0.36		$	0.32		$	0.82		$	0.75
Diluted	$	0.34		$	0.29		$	0.77		$	0.65

Weighted-average of common shares used in income per share calculation
Basic		35,192			33,464			35,103			30,676
Diluted		37,135			36,398			37,182			35,676

Exhibit 99.3

ADAMS RESPIRATORY THERAPEUTICS ANNOUNCES RESIGNATION OF

CHIEF FINANCIAL AND ADMINISTRATIVE OFFICER AND TREASURER

Rita M. O’Connor Succeeds David P. Becker as Chief Financial Officer and Treasurer

CHESTER, N.J. (Feb. 7, 2007) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced that David P. Becker, chief financial and administrative officer and treasurer, has announced his resignation from the Company to accept a position as chief executive officer of a privately held medical diagnostics company. Effective today, Becker will resign from his current position, but will remain as an employee of Adams during a transition period until Feb. 28.

The Company also announced today that Rita M. O’Connor, senior vice president and corporate controller will succeed Becker as the new chief financial officer and treasurer, effective immediately.

Michael J. Valentino, president and chief executive officer said, “In developing a successful company, it is not uncommon to see internal management become externally recognized. This is certainly the case with Dave. His dedication to our business and his exemplary execution on a number of strategic initiatives over time is deeply appreciated. Dave’s new appointment is a testament to his many talents and an acknowledgement of his successful career in the financial and healthcare industries.”

Becker will participate, as planned, in the Company’s conference call at 9:00 a.m. (ET) today to review Adams’ fiscal 2007 second quarter results. He will also attend the Company’s presentation at Merrill Lynch’s 18^th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference in New York City on Thursday, Feb. 8, 2007.

About Adams Respiratory Therapeutics, Inc.

# # #

Investor/Media Contact: Janet M. Barth (908) 879-2428
Source: Adams Respiratory Therapeutics, Inc.

Exhibit 99.4

ADAMS RESPIRATORY THERAPEUTICS ANNOUNCES PROMOTION OF
RITA M. O’CONNOR TO CHIEF FINANCIAL OFFICER AND TREASURER

CHESTER, N.J. (Feb. 7, 2007) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced that Rita M. O’Connor has been promoted to chief financial officer and treasurer, effective immediately. She succeeds David P. Becker, chief financial and administrative officer and treasurer, who announced his resignation from the Company to accept a position as chief executive officer of a privately held medical diagnostics company.

Michael J. Valentino, president and chief executive officer said, “I am very pleased to announce the promotion of Rita to chief financial officer and treasurer. Since joining Adams two years ago, Rita has proven to be a very valuable member of the executive team, and the Board of Directors joins me in enthusiastically supporting her in this new leadership position.”

Before joining Adams in November 2004, O’Connor spent seven years at Schering-Plough Corporation working in a series of positions of increasing responsibility within the corporate global finance department. More recently, she was senior director planning & reporting, within the corporate controller’s group.

She began her career in the audit department at Deloitte and Touche, where she progressed to audit manager, including a two-year program in Deloitte’s National Office technical accounting research department. O’Connor has a B.S. degree in accounting from Rutgers University and is a certified public accountant.

About Adams Respiratory Therapeutics, Inc.

# # #

Investor/Media Contact: Janet M. Barth (908) 879-2428
Source: Adams Respiratory Therapeutics, Inc.